NASDAQ:MSLE Satellos Bioscience Q4 2025 Earnings Report $9.32 -0.36 (-3.72%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$9.32 0.00 (0.00%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Satellos Bioscience EPS ResultsActual EPS-$0.47Consensus EPS -$0.36Beat/MissMissed by -$0.11One Year Ago EPSN/ASatellos Bioscience Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASatellos Bioscience Announcement DetailsQuarterQ4 2025Date3/27/2026TimeBefore Market OpensConference Call DateFriday, March 27, 2026Conference Call Time8:00AM ETConference Call ResourcesPress ReleaseAnnual Report (40-F)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress ReleaseAnnual report(40-F) Satellos Bioscience Earnings HeadlinesSatellos Bioscience to Showcase Forazapadin Program at World Muscle Society CongressSeptember 15, 2026 | tipranks.comSatellos to Present at the 31st Annual Congress of the World Muscle SocietySeptember 15, 2026 | markets.businessinsider.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.September 20 at 1:00 AM | Profits Run (Ad)Satellos Names Forazapadin As INN For Lead DMD Drug CandidateSeptember 9, 2026 | rttnews.comSatellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247September 9, 2026 | markets.businessinsider.comLifeSci Capital Sticks to Their Buy Rating for Satellos Bioscience (MSLE)September 2, 2026 | theglobeandmail.comSee More Satellos Bioscience Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Satellos Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Satellos Bioscience and other key companies, straight to your email. Email Address About Satellos BioscienceSatellos Bioscience (NASDAQ:MSLE) is a biotechnology company focused on developing regenerative medicines for conditions involving skeletal muscle damage, degeneration, or impaired repair. The company’s research is based on the role of muscle stem cells, also known as satellite cells, in maintaining and regenerating muscle tissue. Satellos’ lead product candidate is SAT-3247, an orally administered small-molecule therapy designed to enhance the activation and function of muscle stem cells. The company is evaluating this approach for potential use in diseases characterized by progressive muscle weakness, including Duchenne muscular dystrophy and other muscle disorders. Satellos Bioscience is headquartered in Vancouver, British Columbia, and is developing its therapies for international pharmaceutical and biotechnology markets. The company’s programs remain investigational, and their safety and effectiveness have not been established for marketing use.View Satellos Bioscience ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingThese 3 Stocks Sit at the Center of NVIDIA’s Cybersecurity PushGold Has Gone Sideways, But These 3 Stocks Haven’tLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in Focus Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
